Ho Robert 4

4 · Neoleukin Therapeutics, Inc. · Filed Mar 18, 2021

Form 4

Period: 2021-03-16

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
2021-03-16+25,000→ 28,000 total
Sale
Common Stock
2021-03-17$11.01/sh−6,497$71,556→ 21,503 total
Exercise/Conversion
Restricted Stock Units
2021-03-16+25,000→ 50,000 total
Exercise: $0.00→ Common Stock (25,000 underlying)

Footnotes (4)

[F1]The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
[F2]Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
[F3]The RSUs will vest as to 1/3 of the total number of shares underlying the award on each of March 16, 2021, March 16, 2022 and March 16, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
[F4]The RSUs do not expire; these securities either vest and settle or are canceled prior to the vesting date.

Documents

1 file